Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 9/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20089043 | 0.85 | ALDH1A1 (0.53) | CYP1A2CYP2C9MAPTALDH1A1CYP2C19 | |
| SCHEMBL20088992 | 0.83 | ALDH1A1 (0.55) | CYP1A2CYP2C9MAPTALDH1A1CYP2C19 | |
| SCHEMBL9761405 | 0.76 | MAPT (0.46) | CYP1A2CYP2C9MAPTALDH1A1CYP2C19 | |
| SCHEMBL20086119 | 0.73 | CYP1A2 (0.55) | CYP1A2CYP2C9MAPTALDH1A1CYP2C19 | |
| SCHEMBL9761426 | 0.73 | CYP1A2 (0.55) | CYP1A2CYP2C9MAPTALDH1A1CYP2C19 | |
| SCHEMBL12993 | 0.73 | ALDH1A1 (0.51) | MAPTALDH1A1PKMHTTKMT2A | |
| SCHEMBL15186307 | 0.73 | LRRK2 (0.45) | CYP1A2CYP2C9MAPTALDH1A1CYP2C19 | |
| SCHEMBL12244483 | 0.72 | NUDT1 (0.41) | MAPTALDH1A1POLBKMT2ASMN1; SMN2 | |
| SCHEMBL3403145 | 0.72 | CYP1A2 (0.61) | CYP1A2CYP2C9MAPTALDH1A1CYP2C19 | |
| SCHEMBL2713198 | 0.72 | CYP1A2 (0.61) | CYP1A2CYP2C9MAPTALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4212523-B1 | PYRAZOLE AMIDE COMPOUNDS AS IRAK INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-11939317-B2 | Amide compounds and method for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| EP-4212523-A1 | PYRAZOLE AMIDE COMPOUNDS AS IRAK INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| EP-4212523-A1 | PYRAZOLE AMIDE COMPOUNDS AS IRAK INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20230115275-A1 | AMIDE COMPOUNDS AND METHOD FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| EP-3532465-B1 | PYRAZOLE AMIDE COMPOUNDS AS IRAK INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2023-03-01 | — | — | EP | disclosed |
| CN-115531387-A | Pyrazole amide compounds useful as IRAK inhibitors | 里格尔药品股份有限公司 | 2022-12-30 | — | — | CN | disclosed |
| US-11530194-B2 | Amide compounds and method for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11530194-B2 | Amide compounds and method for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| CN-110234637-B | Pyrazole amide compounds useful as IRAK inhibitors | 里格尔药品股份有限公司 | 2022-11-01 | — | — | CN | disclosed |
| US-20210214342-A1 | AMIDE COMPOUNDS AND METHOD FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2021-07-15 | — | — | US | disclosed |
| US-20210214342-A1 | AMIDE COMPOUNDS AND METHOD FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2021-07-15 | — | — | US | disclosed |
| US-10947216-B2 | Amide compounds and method for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-10947216-B2 | Amide compounds and method for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-10414753-B2 | Amide compounds and method for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-10414753-B2 | Amide compounds and method for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| WO-2018081294-A1 | PYRAZOLE AMIDE COMPOUNDS AS IRAK INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2018-05-03 | — | — | WO | disclosed |
| US-20180111917-A1 | AMIDE COMPOUNDS AND METHOD FOR MAKING AND USING | MIDCAP FINANCIAL TRUST | 2018-04-26 | — | — | US | disclosed |
| US-20180111917-A1 | AMIDE COMPOUNDS AND METHOD FOR MAKING AND USING | MIDCAP FINANCIAL TRUST | 2018-04-26 | — | — | US | disclosed |
| US-5026694-A | Antitumor agents | THE BRITISH COLUMBIA CANCER FOUNDATION (CA) | 1991-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947216-B2 | Amide compounds and method for making and using | IRAK1, IRAK2, IRAK3 | CYP1A2 3695/4885CYP2C9 3985/4885MAPT 2634/4885 |
| US-20230115275-A1 | AMIDE COMPOUNDS AND METHOD FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | CYP1A2 3695/4885CYP2C9 3985/4885MAPT 2634/4885 |
| US-20180111917-A1 | AMIDE COMPOUNDS AND METHOD FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | CYP1A2 3695/4885CYP2C9 3985/4885MAPT 2634/4885 |
| US-11939317-B2 | Amide compounds and method for making and using | IRAK1, IRAK2, IRAK3 | CYP1A2 3695/4885CYP2C9 3985/4885MAPT 2634/4885 |
| US-10414753-B2 | Amide compounds and method for making and using | IRAK1, IRAK2, IRAK3 | CYP1A2 3695/4885CYP2C9 3985/4885MAPT 2634/4885 |
| US-11530194-B2 | Amide compounds and method for making and using | IRAK1, IRAK2, IRAK3 | CYP1A2 3695/4885CYP2C9 3985/4885MAPT 2634/4885 |
| US-20210214342-A1 | AMIDE COMPOUNDS AND METHOD FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | CYP1A2 3695/4885CYP2C9 3985/4885MAPT 2634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.